On August 25, 2026, Zymeworks Inc. announced that partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii) regimens for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. This regulatory milestone triggered a $250 million payment to Zymeworks, bringing total upfront and milestone payments from Jazz to $650 million. The company remains eligible for up to $1.3 billion in additional regulatory and commercial milestones plus tiered royalties of 10% to 20% on net sales. Zymeworks is a biotechnology company managing licensed healthcare assets and developing novel multifunctional biotherapeutics.

Zymeworks Inc. reported second quarter 2026 financial results with total revenue of $4.6 million and a net loss of $45.0 million, compared to $48.7 million in revenue and a $2.3 million net income in the prior year period. The company holds $322.5 million in cash resources as of June 30, 2026. Key developments include an August 25, 2026 U.S. PDUFA target action date for zanidatamab, which carries a potential $250 million approval milestone, and the expected closing of the Theravance Biopharma acquisition in the second half of 2026 to diversify revenue streams. Additionally, Zymeworks repurchased $49.4 million of common shares under its current program. The company operates as a biotechnology firm managing licensed healthcare assets and developing biotherapeutics.

Zymeworks Inc. entered into a merger agreement with Theravance Biopharma, Inc. to acquire it as a wholly owned subsidiary. Shareholders of Theravance will receive $17.00 in cash per share and one contingent value right (CVR) per share. The transaction is expected to close in the second half of 2026 and is being financed through a combination of cash on hand and $350 million in senior secured notes. Zymeworks is a biotechnology company focused on developing biopharmaceutical products.